Andrea S. Blevins Primeau

Adjuvant adoptive cellular immunotherapy plus chemotherapy improved survival in patients with resected non-small cell lung caner.

Recommendations to include CT scans as standard follow-up procedure is based on poor evidence.

A phase 3 trial examined the efficacy of chemoimunnotherapy vs chemotherapy alone in postsurgical patients with non-small cell lung cancer.

Palifosfamide added to carboplatin and etoposide did not prolong survival among patients with extensive-stage small-cell lung cancer.

Researchers considered the response rate “encouraging” and comparable to cisplatin-based neoadjuvant therapy outcomes.

Increased radiation therapy based on midtreatment residual tumor FDG-PET may improve local control among patients with advanced NSCLC.

Adjuvant gefitnib increases disease-free survival for patients with stage II to III non-small lung cancer.

Participants in the phase 3 PACIFIC trial randomly received sequential treatment with either durvalumab or placebo.

Chromosome instability was associated with an increased risk of recurrence and mortality among patients with early-stage non-small cell lung cancer.